Pleotropic Effects of Polyphenols in Cardiovascular System

• Main Authors: Tapan Behl, Simona Bungau, Keshav Kumar, Gokhan Zengin, Fazlullah Khan, Arun Kumar, Rajwinder Kaur, Thangaval Venkatachalam, Delia Mirela Tit, Cosmin Mihai Vesa, Ghita Barsan, Danut-Eugeniu Mosteanu
• Format: Article
• Language: English
• Published: Elsevier 2020-10-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Polyphenol; Cardiovascular disease; Platelet aggregation; Antioxidant defenses; Hyperlipidemia
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332220309070

Numerous epidemiological and clinical studies demonstrate the beneficial effects of naturally occurring, polyphenol supplementations, on cardiovascular system. The present review emphasizes on the risk factors associated with cardiovascular disorders (involving heart and blood vessels), and overview of preclinical and clinical trials on polyphenols for the treatment of cardiovascular diseases. The review collaborates PUBMED, Google Scholar and Research gate databases, which were explored using keywords and their combinations such as polyphenols, cardiovascular disease, flavonoids, atherosclerosis, cardiovascular risk factors and several others, to create an eclectic manuscript. The potency and efficacy of these polyphenols are mainly depending upon the amount of consumption and bioavailability. Recent data showed that polyphenols also exert beneficial actions on vascular system by blocking platelet aggregation and oxidation of low-density lipoprotein (LDL), ameliorating endothelial dysfunction, reducing blood pressure, improving antioxidant defenses and alleviating inflammatory responses. Several studies evidently support the cardioprotective actions mediated by polyphenols, however, some studies or long-term follow-up of human studies, did not demonstrate decisive outcomes because of variations in dose regimen and lack of appropriate controls. Therefore, more data is required to explore the therapeutic benefits of bioactive compounds as a preventive therapy for CVDs.